Literature DB >> 19579793

Influence of conformational antibodies on dissociation of fibrillar amyloid beta (A beta 1-42) in vitro.

Sarada Subramanian1, Sowmya Madhavadas, Preetha Balasubramanian.   

Abstract

Many neurodegenerative diseases result due to the accumulation of misfolded proteins as amyloid fibrils. Although the protein components of these fibrils from different disease states differ considerably, they appear to share common structure. Among these conformational disorders, Alzheimer's disease (AD) and prion diseases exhibit significant overlap in their mechanism of pathogenesis. The present report demonstrates that antibodies directed against the prion protein repeat motif, Tyr-Tyr-Arg motif, recognize recombinantly expressed human amyloid beta (A beta) aggregates in enzyme linked immunosorbent assay. In addition, these antibodies dissociate the preformed aggregates of A beta in vitro. These findings illustrate an important property of conformation dependent antibodies viz., they specifically recognize the protein deposits associated with pathology and not the protein in normal tissue. These antibodies may benefit the development of approaches towards prevention and treatment of protein misfolding diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19579793

Source DB:  PubMed          Journal:  Indian J Exp Biol        ISSN: 0019-5189            Impact factor:   0.818


  2 in total

1.  Pseudocatalytic Antiaggregation Activity of Antibodies: Immunoglobulins can Influence α-Synuclein Aggregation at Substoichiometric Concentrations.

Authors:  Leonid Breydo; Dave Morgan; Vladimir N Uversky
Journal:  Mol Neurobiol       Date:  2015-04-02       Impact factor: 5.590

2.  Development of a dot blot assay with antibodies to recombinant "core" 14-3-3 protein: Evaluation of its usefulness in diagnosis of Creutzfeldt-Jakob disease.

Authors:  Sarada Subramanian; Anita Mahadevan; Parthasarathy Satishchandra; Susarla Krishna Shankar
Journal:  Ann Indian Acad Neurol       Date:  2016 Apr-Jun       Impact factor: 1.383

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.